高级检索
当前位置: 首页 > 详情页

Protocatechuic aldehyde ameliorates psoriasis-like skin inflammation and represses keratinocyte-derived IL-1α and CXCL9 via inhibiting STAT3 activation

文献详情

资源类型:
Pubmed体系:
机构: [1]Engineering Research Center of Sichuan-Tibet Traditional Medicinal Plant, Chengdu University, Chengdu 610106 China [2]Institute of Cancer Biology and Drug Discovery, Chengdu University, Chengdu 610106 China [3]School of Food and Biological Engineering, Chengdu University, Chengdu 610106 China [4]School of Pharmacy, Chengdu University, Chengdu 610106 China [5]School of Basic Medical Sciences, Chengdu University, Chengdu 610106 China [6]Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437 China
出处:
ISSN:

关键词: Psoriasis Protocatechuic aldehyde Inflammation STAT3 Ttranscription Keratinocyte

摘要:
Psoriasis is a chronic inflammatory skin disease. Consistent activation of Signal Transducer and Activator of Transcription 3 (STAT3) in epidermal keratinocyte transactivates various keratinocyte-derived pro-inflammatory cytokines and elicits spontaneous psoriasis-like skin inflammation. In the current study, we first report that topical application of protocatechuic aldehyde (PA), the bioactive compound from Salvia miltiorrhiza (Danshen), significantly improved psoriasis-like skin symptoms and reduced immune cell infiltration in psoriatic lesions. Further molecular mechanism studies demonstrated that PA inactivated STAT3 and inhibited STAT3-mediated transactivation of interleukin-1α (IL-1α) and C-X-C motif chemokine ligand 9 (CXCL9) in epidermal keratinocyte both in vivo and in vitro. Knockdown of STAT3 attenuated the repression effect on IL-1α and CXCL9 by PA. Our results suggested that PA repressed the transactivation of IL-1α and CXCL9 through inhibiting STAT3 in keratinocyte. PA could be potentially used for psoriasis topical treatment or be as a lead compound for drug development.Copyright © 2025 Elsevier B.V. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 免疫学 2 区 药学
第一作者:
第一作者机构: [1]Engineering Research Center of Sichuan-Tibet Traditional Medicinal Plant, Chengdu University, Chengdu 610106 China [2]Institute of Cancer Biology and Drug Discovery, Chengdu University, Chengdu 610106 China [3]School of Food and Biological Engineering, Chengdu University, Chengdu 610106 China
共同第一作者:
通讯作者:
通讯机构: [1]Engineering Research Center of Sichuan-Tibet Traditional Medicinal Plant, Chengdu University, Chengdu 610106 China [2]Institute of Cancer Biology and Drug Discovery, Chengdu University, Chengdu 610106 China [5]School of Basic Medical Sciences, Chengdu University, Chengdu 610106 China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:53699 今日访问量:0 总访问量:4607 更新日期:2025-02-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号